Starting Dose When Switching from Ozempic 1mg to Wegovy
When transitioning from Ozempic 1 mg to Wegovy in a 62-year-old woman, start with Wegovy 0.25 mg weekly and follow the standard titration schedule, not at 1 mg or higher. This is the FDA-approved approach and reflects the fact that Wegovy and Ozempic, while both containing semaglutide, are dosed differently for their respective indications 1.
Rationale for Starting at 0.25 mg
The FDA label for Wegovy explicitly states that semaglutide for obesity "is titrated up from a starting or initial dose of 0.25 mg weekly and titrated monthly as tolerated up to a maximum dose of 2.4 mg weekly" 2. This applies to all patients initiating Wegovy, regardless of prior semaglutide exposure at lower doses for diabetes management.
Why Not Start at 1 mg?
- Different therapeutic context: Ozempic 1 mg is optimized for glycemic control in type 2 diabetes, while Wegovy targets weight loss with higher final dosing (2.4 mg) 2
- GI tolerability: The gradual titration from 0.25 mg minimizes gastrointestinal adverse events (nausea, vomiting, diarrhea), which are the most common side effects and primary reason for discontinuation 3
- No direct switching protocol exists: The FDA label and current guidelines 2, 1 do not provide an alternative "fast-track" titration for patients already on lower-dose semaglutide
Standard Wegovy Titration Schedule
Follow this monthly escalation 1:
- Weeks 1-4: 0.25 mg weekly
- Weeks 5-8: 0.5 mg weekly
- Weeks 9-12: 1.0 mg weekly
- Weeks 13-16: 1.7 mg weekly
- Week 17 onward: 2.4 mg weekly (maintenance dose)
Important Considerations
Individualized dosing may be appropriate: Recent real-world data shows that many patients achieve satisfactory weight loss and clinical benefit at 1 mg without progressing to 2.4 mg 4. In one Danish survey, 45% of users remained on 1 mg with median weight loss of 12% at 3-6 months and 17% at 6-12 months—comparable to those on higher doses 4. Additionally, 24% of patients reduced or discontinued concomitant medications (especially for hypertension and joint pain) while on 1 mg 4.
If GI side effects occur: Delay dose escalation by 4 weeks. In clinical trials, 86.7% of patients reached the 2.4 mg dose, but 5% found 1.7 mg to be their maximum tolerated dose 1.
Cardiovascular benefit: The SELECT trial demonstrated that semaglutide 2.4 mg reduces major adverse cardiovascular events by 20% in patients with established CVD and obesity (without diabetes) 2. If this patient has cardiovascular disease, reaching the 2.4 mg dose is particularly important for secondary prevention.
Common Pitfalls to Avoid
- Do not skip the titration: Starting at 1 mg or higher dramatically increases risk of severe nausea/vomiting and treatment discontinuation
- Do not use "click counting": 10% of users in real-world settings dose by counting pen clicks rather than following prescribed doses—this leads to inconsistent dosing 4
- Do not assume prior tolerance predicts future tolerance: Even patients stable on Ozempic 1 mg may experience GI symptoms when escalating to higher Wegovy doses